Influenza-like illness (ILI) presents with sudden onset systemic and respiratory symptoms, including fever, fatigue and myalgia, and requires timely symptomatic management. Anas barbariae 200K (Oscillococcinum®) is a homeopathic medicinal product traditionally used to relieve flu-like symptoms. The trial reported here aimed to assess whether Anas barbariae 200K provides superior alleviation of ILI symptoms within 72 hours compared with placebo, and to evaluate secondary outcomes including symptom relief kinetics, functional recovery, compliance, satisfaction and safety.
This was a prospective, randomized, double-blind, placebo-controlled multicenter superiority trial with two parallel groups conducted in primary care sites in India in 2021. The protocol and registration are reported to Clinical Trials Registry of India (CTRI/2021/02/031250), registered on February 12, 2021. Ethical approvals were obtained from multiple independent ethics committees named in the report.
Eligible participants were children aged 6–12 years and adults aged 18–65 years presenting with ILI symptoms of less than 24 hours’ duration. Participants were randomized to receive either Anas barbariae 200K (Oscillococcinum®) or matching placebo. The assigned study product was administered three times daily for three days. A total of 707 participants received treatment: 352 in the Anas barbariae 200K arm and 355 in the placebo arm.
The primary endpoint was the proportion of participants with alleviation of ILI symptoms within 72 hours after treatment initiation. Secondary outcomes included time to symptom alleviation, median time to return to daily activities assessed by Kaplan–Meier analysis, adverse events, compliance, and participant and investigator satisfaction.
In the intent-to-treat population reported, the primary endpoint favored Anas barbariae 200K. Within 72 hours, 74% of participants in the Anas barbariae 200K group achieved symptom alleviation compared with 44.5% in the placebo group; this difference was reported as statistically significant (p < 0.0001).
Secondary outcome measures also favored the active treatment. Mean (or reported) time to symptom alleviation was shorter in the Anas barbariae 200K arm (46.7 hours) versus placebo (67.3 hours), with a reported p value < 0.0001. Median time to return to daily activities estimated by Kaplan–Meier analysis was 4.0 days for the Anas barbariae 200K group versus 6.0 days for placebo, also reported as statistically significant (p < 0.0001).
The authors described these improvements as both statistically and clinically significant across the primary and reported secondary outcomes.
The study report states that no serious adverse events were reported and that no safety signal was identified. The source provides no additional detail on non-serious adverse event rates, specific adverse event types, or withdrawal rates due to adverse events beyond the statement that no serious events occurred.
The trial is registered in the Clinical Trials Registry of India under CTRI/2021/02/031250 (registration date February 12, 2021). Ethical approvals were obtained from The Royal Pune Independent Ethics Committee, the Independent Ethics Committee Healthpoint Hospital, the Institutional Ethics Committee Panchsheel Hospital, the Institutional Ethics Committee Narayana Diagnostic, and the Vagus Institutional Ethics Committee. The authors state that all necessary participant consent and IRB/oversight approvals were obtained. The report indicates that all study data are available from the corresponding author on reasonable request.
The report discloses that several investigators (MaG, AT, MG, and PC) received fees for including and treating participants. Two authors (IC and SC) were employed by Laboratoires Boiron, and one author (NB) was employed by Laboratoires Boiron at the time of the study. The declared funder of the trial is Boiron (France). The manuscript states these competing interests and funding relationships.
The authors conclude that Anas barbariae 200K significantly alleviated ILI symptoms within 72 hours compared with placebo, with faster symptom relief and earlier return to daily activities, and that the treatment was well tolerated with no safety signal identified.
The source document does not present an explicit limitations section in the provided text; therefore, specific limitations discussed by the authors (for example, details on blinding integrity, symptom assessment methods, virologic confirmation of influenza, or subgroup analyses) were not reported in the supplied content.
According to the trial report, Anas barbariae 200K (Oscillococcinum®) may offer faster symptomatic relief and earlier functional recovery for patients presenting early (within 24 hours) with ILI in the studied age ranges, and no serious safety concerns were reported in this dataset. Clinicians and readers should note the declared industry funding and employment relationships reported by some authors and consider the full study report and data, which the authors state are available on reasonable request, when interpreting applicability and generalizability.